RxDoctor Payments Data

Wesley O'Neal, MD

Cardiovascular Disease · Greensboro, NCNPI 1437596269

Payments from drug & device makers

$107,998in general payments, 2019–2025

Across 231 payments — averaging $467.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$91K
  • BD$10K
  • Abbott$2K
  • GE HealthCare$2K
  • Artrya Ltd.$1K
  • Amgen$463
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$32,84538%
  • Speaking & faculty fees$44,88553%
  • Travel & lodging$3,0344%
  • Food & beverage$4,6165%
  • Education$180%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$107,998 in reported general payments places this provider in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$64,986
Medicare patients
730
Services billed
1,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WainuaEplontersen Sodium13$551,999
VyndamaxTafamidis24$523,108
EliquisApixaban415$364,304
EntrestoSacubitril/Valsartan107$150,177
Repatha SureclickEvolocumab116$107,078
JardianceEmpagliflozin107$99,054
XareltoRivaroxaban47$37,051
FarxigaDapagliflozin Propanediol40$36,860
Metoprolol Succinate294$3,520
Atorvastatin Calcium292$3,322
Rosuvastatin Calcium260$2,957
Ezetimibe146$2,182
Losartan Potassium163$2,166
Torsemide66$1,767
Spironolactone211$1,600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$164$887,412439 claims
AstraZenecaWainua, Farxiga$230$588,85953 claims
NovartisEntresto$262$150,177107 claims
Boehringer IngelheimJardiance$79$99,054107 claims
Johnson & JohnsonXarelto$37$37,05147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →